NaturaLase LP and NaturaLight Family of Products 510(k) Submission
SEP ~ 7 2004 Section 16
510(k) Summary
This 510(k) summary of safety and effectiveness for the Focus Medica} NaturaLase LP
aud NaturaLight Family of Products is submitted is accordeace wiih the requirements of
SMDA 1990 and follows Office of Device Evaluation guidance concerning the
organization and content of a 510(k) summary.
Applicant: Focus Medical
Address:
Focus Medical, LLC
23 Francis J. Clarke Circle
Bethel, CT 06801
Contact Person: Mr. John B. Lee, Jr.
President
Focus Medical
Telephone: 203-730-8885
Preparation Date: June 2004
(of the Summary)
Device Name:
NaturaLase LP and NaturaLight Family of Products
Common Name:
Nd:YAG and Intense Pulsed Light treatment system
Classification:
Laser surgical instrument for use in general and plastic surgery and in dermatology.
Class II medical device
21CFR 878.4810
Product Code: GEX
Panel: 79
Predicate devices:
Palomar Starlux Pulsed Light System (K033549)
Lumenis Family of Intense Pulsed Light (IPL) and IPL/Nd: YAG Lasex Systems
(K030527)
T.umenis IPE. Quantum Family of Products (K020839)
Focus Medical NaturaLase LP (K031828)
Page 101 of 104 .

NaturaLase LP and NaturaLight Family of Products 510(k) Submission
Ko41829 of of F

Device description:
The Focus Medical Naturalase LP and NaturaLight Family of Products consists of the
NaturaLase LP Nd:YAG Laser System, the NaturaLight IPL System and the Natura! asc
LP+ a simple combinatici of the NaturaLase LP and the Natural_ight.
Indications for Use: .
NaturaLighi Indications for Use
NaturaLight IPL System and the NaturaLase LP+ System when used in IPL (intense
pulsed light) Mode is indicated for:

Dermatology/Viastic Surgery:
The removal of unwanted hair from skin types I-VJ, and to effect stable long-term, or
permanent, hair reduction.
The treatment of benign pigmented lesions, including lentigines, nevi, melasma, and
cafe-au-lait. treatment of vascular lesions, including port wine stains, hemangiomas,
angiomas, telangiectasias, rosacea, facial and leg veins.
NaturaLase LP Indications For Use
The Focus Medical NaturaLase LP Laser System and the NaturaLase LP+ System when
used in Laser Mode is indicated for:

General Surgical Applications:
Incision, excision, coagulation, hemostasis, vaporization, and/or ablation of soft tissue in
dermatology/plastic surgery, endoscopic/laparoscopic general surgery, gastroenterology,
general surgery, gynecology, head and neck/ otorhinolaryngology (ENT), neurosurgery,
oculoplastics, orthopedics, pulmonary surgery, thoracic surgery, and urology.

Dermatology/Plastic Surgery:
Coagulation and hemostasis of benign vascular lesions such as port wine stains,
hemangiomas, warts, telangiectasia, rosacea, venus lake, leg and spider veins. In
addition, the NaturaLase LP is intended for the treatment of benign pigmented lesions
such as, but not limited to, lentigos (age spots), solar lentigos (sun spots), café au ait
macules, scborrhcic keratoses, nevi chloasma, verrucae, skin tags, keratoses, tattoos
(significant reduction in the intensity of black and/or blue/black tattoos) and plaques.
‘The NaturalLase LLP Laser is also indicated for pigmented lesions to reduce lesion size, for
patients with lesions that would potentially benefit from aggressive t:eatinent, and for
patients with Jesions that have not responded to other laser treatments.
Cu‘ting, incision, excision, hemostasis, coagulation, vaporization and ablation of soft
tissuc in dermatology and plastic surgery.
The NaturaLase LP Laser is also indicated for the treatment of facial wrinkles and
wrinkles such as, but not limited to, periocular and periorbital wrinkles.
The NaturaLase LP Laser is indicated for the removal of unwanted hair, for the stable
Jong tem, or permanent, hair reduction through sclective targeting of melanin in hair
follicles, and for the treatment for pscudofolliculilis barbae (PFB).

Page 102 of 104

NaturaLase LP and NaturaLight Family of Products 510(k) Submission 1929 3g
Ko4 4
The NaturaLase LP Laser is indicated for the reduction of red pigmentation in
hypertrophic and keloid scars where vascularity is an integral part of the scar.
oO The. Naturalase LP Laser is indicated for use on all skin types (Fitzpatrick I - VI)

including lanned skin.

Endoscopic/Laparoscopic Surgery:
‘The NaturaLase LP Laser is also indicated for usc in a variety of surgical procedures in
several surgical specialties. These include, but not limited to, cholecystectomy,
appendectomy, vagotomy, and pyloromyomotomy where its abililies to incisc, excise,
coagulate, vaporize, or ablate soft tissue may be applied.

Gastroenterology:
Tissue ablation and hemostasis in the gastrointestinal tract; esophagea! neoplastic
obstruction including squamous cell carcinoma and adenocarcinoma, gastrointestinal
hemostasis including varices, esophagitis, esophageal ulcer, Mallory-Weiss tear, gastric
ulcer, angiodysplasia, stomal ulcers, non-bleeding ulcers, gastric erosions,
gastrointestinal tissue ablation including benign and malignant neoplasm, angiodysplasia,
polyps, ulcer, colitis, and hemorrhoids.

General Surgery:
Incision, excision, vaporization, ablation, and hemostasis of soft tissue general surgery
applications, skin incisions, tissue dissection, excision of external tumors and lesions,
complete or partial resection of internal organs, tumors, lesions, tissue ablation, vessel
coagulation, tonsillectomy, and hemorrhoids.

Gynecology:
Treatment of menorrhagia by photocoagulation of the endometrial lining of the uterus,
ablation of endometrial implants and/or peritoneal adhesions, soft tissue excisional
procedures such as excisional conization of the cervix, intrauterine gynecologic
procedures where cutting, ablation, and/or vessel coagulation may be indicated including
submucous fibroids, benign endometrial polyps, and uterine septum.

Head and Neck/Otorhinolaryngology (ENT):
Tissue incision, excision, ablation, and vessel hemostasis.

Hemostasis During Surgery:
Adjunctive coagulation and hemostasis (bleeding control) during surgery in endoscopic
(c.g. laparoscepic) and open procedures.

Neurosurgery:
Hemostasis for pituitary tumor, meningioma, hemagioblastoma, AVMs. glioblastoma,
astrocytoma, oligodendroglioma.

Oculoplastics:
Incision, excision, vaporization, and/or coagulation of tissues in oculoplastic procedures
such as operations on the lacrimal system, operation on the eyclids, removal of biopsy or
orbital tumors, enucleation on cychall, exteneration of orbital contents.

Page 103 of 104

NaturaLase LP and NaturaLight Family of Products 510(k) Submission
Koy929 F of F

Orthopedics:
Cutting, ablation, and/or hemostasis of intra-articular tissue m orthopedic surgical and
arthroscopic applications. :

Pulmonary Surgery: .
Palliative treatment of benign and malignant pulmonary airway obstructions, including
Squamous cell carcinoma, adenocarcinoma, carcinoid, benign tumors, granulomas, and
benign strictures.

Thoracic Surgery:
Cutting (incision/excision), coagulating, and vaporization of soft tissue. Thoracic
applications including, Lut not limited to, isolation of vessels for endarterectomy and/or
by-pass grafts, wedge resections, thoractomy, formation of pacemaker pockets;
vaporization, coagulation, incision/excision, debulking, and ablation of lung tissue
(thoracoscopy).

Urology:
All applications including superficial urinary bladder tumors, invasive bladder
carcinoma, urethral strictures and lesions of the external genitalia (including condyloma
acuminata).

Page 104 of 104

eng
i & DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
a
Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850
SEP - 7 2004
Mr. John B. Lee, Jr.
President .
Focus Medical, LLC
23 Francis J Clarke Circle
Bethel, Connecticut 06801
Re: K041829
Trade/Device Name: NaturaLase LP and NaturaLight Family of Products
Regulation Number: 21 CFR 878.4810
Regulation Name: Laser surgical instrument for use in general and
plastic surgery and in dermatology
Regulatory Class: II
Product Code: GEX
Dated: July 7, 2004
Received: July 12, 2004
Dear Mr. Lee:
We have reviewed your Section 510(k) premarket notification of intent to market the device
referenced above and have determined the device is substantially equivalent (for the indications
for use stated in the enclosure) to legally marketed predicate devices marketed in interstate
commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to
devices that have been reclassified in accordance with the provisions of the Federal Food, Drug,
and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).
You may, therefore, market the device, subject to the general controls provisions of the Act. The
general controls provisions of the Act include requirements for annual registration, listing of
devices, good manufacturing practice, labeling, and prohibitions against misbranding and
adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it
may be subject to such additional controls. Existing major regulations affecting your device can
be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may
publish further announcements concerning your device in the Federal Register.
Please be advised that FDA’s issuance of a substantial equivalence determination does not mean
that FDA has made a determination that your device complies with other requirements of the Act
or any Federal statutes and regulations administered by other Federal agencies. You must
comply with all the Act’s requirements, including, but not limited to: registration and listing (21
CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic
product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 - Mr. John B. Lee, Jr.
This letter will allow you to begin marketing your device as described in your Section 5 10(k)
premarket notification. The FDA finding of substantial equivalence of your device to a legally
marketed predicate device results in a classification for your device and thus, permits your device
to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please
contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled,
"Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain
other general information on your responsibilities under the Act from the Division of Small
Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or
(301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Muon, C- Poveat
Celia M. Witten, Ph.D., M.D.
Director
Division of General, Restorative
and Neurological Devices

Office of Device Evaluation

Center for Devices and Radiological Health
Enclosure

Indications for Use
510(k) Number (if known):K041829
Device Name:
Indications For Use:
NaturaLight IPL System (intense pulsed light) is indicated for:
The removal of unwanted hair from skin types I-VI, and to effect stable long-term, or
permanent, hair reduction. The treatment of benign pigmented lesions, including
lentigines, nevi, melasma, and cafe-au-lait. treatment of vascular lesions, including port
wine stains, hemangiomas, angiomas, telangiectasias, rosacea, facial and leg veins.
NaturaLase LP Indications For Use
The Focus Medical NaturaLase LP Laser System and the NaturaLase LP+ System
when used in Laser Mode is indicated for:
General Surgical Applications:
Incision, excision, coagulation, hemostasis, vaporization, and/or ablation of soft tissue
in dermatology/plastic surgery, endoscopic/laparoscopic general surgery,
gastroenterology, general surgery, gynecology, head and neck/ otorhinolaryngology
(ENT), neurosurgery, oculoplastics, orthopedics, pulmonary surgery, thoracic surgery,
and urology.
Prescription Use X AND/OR Over-The-Counter Use
(Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF
NEEDED) .
Concurrence of CDRH, Office of Device Evaluation (ODE)
(Division Sign-Off)
ees . Page 1 of 4
Division of General, Restorative,
and Neurological Devices
510(k) Number_427/827

Continuation for Indications for Use on Form FDA 3514 Section G Page 2
Dermatology/Plastic Surgery:

Coagulation and hemostasis of benign vascular lesions such as port wine stains,
hemangiomas, warts, telangiectasia, rosacea, venus lake, leg and spider veins. In
addition, the NaturaLase LP is intended for the treatment of benign pigmented lesions
such as, but not limited to, lentigos (age spots), solar lentigos (sun spots), café au lait
macules, seborrheic keratoses, nevi chloasma, verrucae, skin tags, keratoses, tattoos
(significant reduction in the intensity of black and/or blue/black tattoos) and plaques.
The NaturaLase LP Laser is also indicated for pigmented lesions to reduce lesion size,
for patients with lesions that would potentially benefit from aggressive treatment, and
for patients with lesions that have not responded to other laser treatments.
Cutting, incision, excision, hemostasis, coagulation, vaporization and ablation of soft
tissue in dermatology and plastic surgery.
The NaturaLase LP Laser is also indicated for the treatment of facial wrinkles and
wrinkles such as, but not limited to, periocular and periorbital wrinkles.
The NaturaLase LP Laser is indicated for the removal of unwanted hair, for the stable
long tem, or permanent, hair reduction through selective targeting of melanin in hair
follicles, and for the treatment for pseudofolliculitis barbae (PFB).
The NaturaLase LP Laser is indicated for the reduction of red pigmentation in
hypertrophic and keloid scars where vascularity is an integral part of the scar.
The NaturaLase LP Laser is indicated for use on all skin types (Fitzpatrick | - VI)
including tanned skin.

Endoscopic/Laparoscopic Surgery:
The NaturaLase LP Laser is also indicated for use in a variety of surgical procedures in
several surgical specialties. These include, but not limited to, cholecystectomy,
appendectomy, vagotomy, and pyloromyomotomy where its abilities to incise, excise,
coagulate, vaporize, or ablate soft tissue may be applied.
Prescription Use __ X AND/OR Over-The-Counter Use
(Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF
NEEDED)
a

Concurrence of CDRH, Office of Device Evaluation (ODE)
inci Oo ee
(Division Sign-Off)
Divis; . Page 2 of 4
aN, of General, Restorative,
and Neurological Devices
510(k) Number_A0 4/839
a alee

Continuation for Indications for Use on Form FDA 3514 Section G Page 3 of F
Gastroenterology:
Tissue ablation and hemostasis in the gastrointestinal tract; esophageal neoplastic
obstruction including squamous cell carcinoma and adenocarcinoma, gastrointestinal
hemostasis including varices, esophagitis, esophageal ulcer, Mallory-Weiss tear, gastric
ulcer, angiodysplasia, stomal ulcers, non-bleeding ulcers, gastric erosions,
gastrointestinal tissue ablation including benign and malignant neoplasm,
angiodysplasia, polyps, ulcer, colitis, and hemorrhoids.
General Surgery:
Incision, excision, vaporization, ablation, and hemostasis of soft tissue general surgery
applications, skin incisions, tissue dissection, excision of external tumors and lesions,
complete or partial resection of internal organs, tumors, lesions, tissue ablation, vessel
coagulation, tonsillectomy, and hemorrhoids.
Gynecology:
Treatment of menorrhagia by photocoagulation of the endometrial lining of the uterus,
ablation of endometrial implants and/or peritoneal adhesions, soft tissue excisional
procedures such as excisional conization of the cervix, intrauterine gynecologic
procedures where cutting, ablation, and/or vessel coagulation may be indicated
including submucous fibroids, benign endometrial polyps, and uterine septum.
Head and Neck/Otorhinolaryngology (ENT):
Tissue incision, excision, ablation, and vessel hemostasis.
Hemostasis During Surgery:
Adjunctive coagulation and hemostasis (bleeding control) during surgery in endoscopic
(e.g. laparoscopic) and open procedures.
Neurosurgery:
Hemostasis for pituitary tumor, meningioma, hemagioblastoma, AVMs. glioblastoma,
astrocytoma, oligodendroglioma.
Prescription Use __ X AND/OR Over-The-Counter Use
(Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF
NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
(Division Sign-Off)
Division of General, Restorative,
and Neurological Devices
510(kK) Number A Ol & az

Continuation for Indications for Use on Form FDA 3514 Section G Page 4
Oculoplastics:
Incision, excision, vaporization, and/or coagulation of tissues in oculoplastic procedures
such as operations on the lacrimal system, operation on the eyelids, removal of biopsy
or orbital tumors, enucleation on eyeball, exteneration of orbital contents.
Orthopedics:
Cutting, ablation, and/or hemostasis of intra-articular tissue in orthopedic surgical and
arthroscopic applications.
Pulmonary Surgery:
Palliative treatment of benign and malignant pulmonary airway obstructions, including
Squamous cell carcinoma, adenocarcinoma, carcinoid, benign tumors, granulomas, and
benign strictures.
Thoracic Surgery:
Cutting (incision/excision), coagulating, and vaporization of soft tissue. Thoracic
applications including, but not limited to, isolation of vessels for endarterectomy and/or
by-pass grafts, wedge resections, thoractomy, formation of pacemaker pockets:
- vaporization, coagulation, incision/excision, debulking, and ablation of lung tissue
(thoracoscopy).
Urology:
All applications including superficial urinary bladder tumors, invasive bladder
carcinoma, urethral strictures and lesions of the external genitalia (including condyloma
acuminata).
Prescription Use __ X AND/OR Over-The-Counter Use
(Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF
NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Mian) C. Kurt
(Division Sign-Off)
Division of General, Restorative, Page 4 of 4
and Neurological Devices
510(k) Number_f27/ 24

